Replimune Group (NASDAQ:REPL) Earns “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Replimune Group (NASDAQ:REPL) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $17.00 price target on the stock.

REPL has been the subject of several other research reports. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.00.

Replimune Group Trading Up 35.1 %

Shares of NASDAQ:REPL opened at $14.93 on Friday. The firm has a fifty day moving average of $11.51 and a two-hundred day moving average of $9.67. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 10.11.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.07. Equities analysts predict that Replimune Group will post -3.02 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,246 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. The trade was a 6.19 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 8.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC bought a new stake in Replimune Group in the first quarter valued at about $927,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Replimune Group during the first quarter worth approximately $1,088,000. Price T Rowe Associates Inc. MD lifted its position in shares of Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock worth $53,505,000 after purchasing an additional 699,679 shares in the last quarter. LMR Partners LLP lifted its holdings in Replimune Group by 145.8% in the third quarter. LMR Partners LLP now owns 82,479 shares of the company’s stock valued at $904,000 after buying an additional 48,920 shares during the period. Finally, Millennium Management LLC lifted its holdings in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock valued at $28,062,000 after buying an additional 2,656,173 shares during the period. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.